We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$740M
AUM Growth
-$43.3M
Cap. Flow
-$86.3M
Cap. Flow %
-11.66%
Top 10 Hldgs %
29.49%
Holding
104
New
10
Increased
27
Reduced
49
Closed
9

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.8M
2
GILD icon
Gilead Sciences
GILD
+$9.89M
3
COR icon
Cencora
COR
+$7.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.72M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$6.41M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$20.2M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$14.8M
3
ABMD
Abiomed Inc
ABMD
+$10M
4
AET
Aetna Inc
AET
+$9.86M
5
CVS icon
CVS Health
CVS
+$9.76M

Sector Composition

Rank Sector Weight
1 Healthcare 90.07%
2 Financials 0.19%
3 Technology 0.17%
4 Energy 0.14%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$28.5M 3.86%
1,954,912
-1,051,950
-35% -$14.8M
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
$25.5M 3.44%
386,626
+74,823
+24% +$4.03M
ADMS
3
DELISTED
Adamas Pharmaceuticals
ADMS
$23.5M 3.17%
692,913
-222,087
-24% -$6.2M
EXEL icon
4
Exelixis
EXEL
$13.3B
$23M 3.11%
756,214
-293,786
-28% -$7.81M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$121B
$22.8M 3.08%
152,204
-27,796
-15% -$4.12M
NKTR icon
6
Nektar Therapeutics
NKTR
$2.39B
$21.1M 2.85%
23,567
-34,179
-59% -$20.2M
GILD icon
7
Gilead Sciences
GILD
$162B
$20.5M 2.77%
285,751
+130,200
+84% +$9.89M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$18.2M 2.45%
151,863
-13,137
-8% -$1.6M
JAZZ icon
9
Jazz Pharmaceuticals
JAZZ
$15.9B
$18M 2.43%
133,436
+48,436
+57% +$6.72M
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$17.3M 2.34%
104,930
+54,930
+110% +$5.33M
CELG
11
DELISTED
Celgene Corp
CELG
$16.8M 2.28%
161,412
+9,412
+6% +$1.06M
UNH icon
12
UnitedHealth
UNH
$376B
$16.6M 2.25%
75,500
-9,500
-11% -$2.01M
ESRX
13
DELISTED
Express Scripts Holding Company
ESRX
$16.5M 2.23%
221,483
-23,517
-10% -$1.5M
ABMD
14
DELISTED
Abiomed Inc
ABMD
$16.2M 2.19%
86,490
-53,748
-38% -$10M
COR icon
15
Cencora
COR
$60.6B
$16M 2.16%
174,261
+94,261
+118% +$7.8M
ITCI
16
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$15.7M 2.12%
1,084,581
-95,319
-8% -$1.47M
GKOS icon
17
Glaukos
GKOS
$9.83B
$15.6M 2.11%
608,400
-39,396
-6% -$1.17M
INCY icon
18
Incyte
INCY
$24.2B
$15.5M 2.09%
163,703
+48,703
+42% +$5.09M
ABBV icon
19
AbbVie
ABBV
$443B
$15.2M 2.05%
156,700
+16,700
+12% +$1.57M
HUM icon
20
Humana
HUM
$43.7B
$14.4M 1.94%
58,000
+17,000
+41% +$4.2M
MDT icon
21
Medtronic
MDT
$109B
$13.3M 1.79%
164,225
-49,890
-23% -$4M
ARNA
22
DELISTED
Arena Pharmaceuticals Inc
ARNA
$13.1M 1.77%
385,642
-183,849
-32% -$5.24M
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.6B
$12.5M 1.69%
139,849
-40,100
-22% -$3.49M
LLY icon
24
Eli Lilly
LLY
$1.02T
$12.1M 1.63%
142,859
+32,859
+30% +$2.8M
REGN icon
25
Regeneron Pharmaceuticals
REGN
$78.5B
$11.7M 1.58%
31,154
+9,154
+42% +$3.71M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Rhenman & Partners Asset Management held 104 positions worth $740M, down 5.5% from $783M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $86.3M in Q4 2017, closing 9 positions and reducing 49 holdings. Its most notable exit was Aetna Inc, an estimated $9.86M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Acadia Pharmaceuticals worth $10.2M.

  • Rhenman & Partners Asset Management's largest Q4 2017 buy was Acadia Pharmaceuticals: 338,882 shares worth $10.2M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q4 2017, an estimated $9.89M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $20.2M.
  • Rhenman & Partners Asset Management fully exited Aetna Inc in Q4 2017, selling an estimated $9.86M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $740M portfolio in Q4 2017.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 9 in Q4 2017.
  • Rhenman & Partners Asset Management's portfolio value fell 5.5% quarter-over-quarter to $740M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2017, filed 19 Jan 2018.